Develop Business Strategies Of Opioid-Induced Constipation Market 2019
"The
Latest Research Report OpportunityAnalyzer: Opioid-Induced
Constipation - Opportunity Analysis and Forecasts to 2019 provides
information on pricing, market analysis, shares, forecast, and
company profiles for key industry participants. -
MarketResearchReports.biz"
About
Opioid-Induced Constipation Market
The Opioid-Induced Constipation
(OIC) is a new and rapidly establishing market currently dominated by
OTC laxatives set to undergo substantial growth between 2014 and
2019. The main drivers of growth will be an increase in the diagnosed
OIC population. This is fuelled by a relaxation of regulations
regarding opioid treatment, particularly in the chronic non-cancer
pain population. As a result opioid use has risen sharply in the last
15 years. Concurrently, there has been a rapid increase in patients
experiencing OIC, with approximately 40-50% of chronic opioid users
reporting symptoms. Traditionally, constipation has been treated with
laxatives based on empirical research. However, the efficacy of
laxatives to treat OIC is relatively poor and only provides adequate
relief for approximately 50% of patients. Prior to 2008, the OIC
market was desolate, with no approved pharmaceutical (non-laxative)
treatment for this condition. The products that have been approved in
the past have come with heavy restrictions limiting their use for the
majority of OIC sufferers. However, the OIC therapeutic market is set
to enter an explosive period of growth over the five-year forecast
period. This advance is catalyzed by a major shift in the OIC
treatment algorithm with the entry of several highlytargeted,
efficacious, orally-formulated drugs. The competitive landscape will
continue to evolve over the forecast period.
Highlights
Key Questions Answered
The OIC market is marked by the
presence of a number of unmet needs in current treatments. What are
the main unmet needs in this market? Will the drugs under development
fulfil the unmet needs of the OIC market?
The late-stage OIC pipeline is
heavily congested with several drugs in the same class, PAMORAs. Will
the late-stage drugs make a significant impact on the OIC market?
Which of these drugs will have the highest peak sales at the highest
CAGR, and why?
The current OIC market is
dominated by OTC laxatives. How will the advent of highly targeted
orally-formulated prescription drugs change the drug treatment
landscape for OIC? How will the drug treatment rate change over the
next five years? What are the key drivers and barriers to this
change?
Key Findings
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/600190
The main driver of the enormous
expansion of the OIC market will be the dramatic increase in the
number of reported OIC cases, which is attributable to the relaxation
of opioid prescribing regulations.
The second largest driver will be
the launch of several highly anticipated, targeted, efficacious
treatment options, with a congested and competitive late stage
clinical pipeline.
To gain approval it is essential
for companies to demonstrate high efficacy while proving no reduction
of analgesia or Major Cardiovascular Adverse Effects (MACE), by
selecting appropriate clinical trial endpoints.
In the future, companies will have
to increase physician and patient awareness of non-laxative
prescription options to treat constipation through extensive
marketing campaigns in order to successfully compete for patient
share.
The number of pipeline agents
being developed by small mid-pharma represents an opportunity for
large pharma to enter this highly lucrative market through licensing
and marketing partnerships.
Scope
Overview of OIC, including
epidemiology, etiology, pathophysiology, symptoms, diagnosis, and
treatment guidelines.
Annualized OIC therapeutics market
revenue, annual cost of therapy and treatment usage pattern data from
2014 and forecast for seven years to 2019.
Key topics covered include
strategic competitor assessment, market characterization, unmet
needs, clinical trial mapping and implications for the OIC
therapeutics market.
Pipeline analysis: comprehensive
data split across different phases, emerging novel trends under
development, and detailed analysis of late-stage pipeline drugs.
Analysis of the current and future
market competition in the global OIC therapeutics market. Insightful
review of the key industry drivers, restraints and challenges. Each
trend is independently researched to provide qualitative analysis of
its implications.
Reasons to buy
The report will enable you to -
Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline. Additionally a list of acquisition
targets included in the pipeline product company list.
Develop business strategies by
understanding the trends shaping and driving the global OIC
therapeutics market.
Drive revenues by understanding
the key trends, innovative products and technologies, market
segments, and companies likely to impact the global OIC therapeutics
market in future.
Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analysing the performance of various competitors.
Identify emerging players with
potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
Track drug sales in the global OIC
therapeutics market from 2014-2019.
Organize your sales and marketing
efforts by identifying the market categories and segments that
present maximum opportunities for consolidations, investments and
strategic partnerships.
Table of Contents
1 Table of Contents
1 Table of Contents 8
1.1 List of Tables 11
1.2 List of Figures 13
2 Introduction 15
2.1 Catalyst 15
Send
An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/600190
3 Disease Overview 17
3.1 Etiology and Pathophysiology
17
3.1.1 Etiology 17
3.1.2 Pathophysiology 19
3.1.3 Quality of Life 20
3.2 Symptoms 22
3.2.1 General Treatment Consensus
in the US and EU 23
4 Potential Patient Population 25
4.1 Overview 25
4.2 General Forecasting
Methodology 26
4.3 Region-Specific Forecast
Methodology 28
4.3.1 Opioid Consumption 28
4.3.2 Number of OIC Cases 29
4.4 Country-Level Differences in
Opioid Consumption 30
4.4.1 US 30
4.4.2 France 34
4.4.3 Germany 37
4.4.4 Italy 40
4.4.5 Spain 43
4.4.6 UK 46
4.5 Potential OIC Patient
Population Forecast 49
4.5.1 Total Number of Cases of OIC
49
5 Current Treatment Options 51
5.1 Overview 51
5.2 Product Profiles - Major
Brands 56
5.2.1 Relistor 56
5.2.2 Targin 64
5.2.3 Amitiza 70
5.2.4 Movantik 78
6 Unmet Needs Assessment and
Opportunity Analysis 84
6.1 Overview 84
6.2 Unmet Needs Analysis 85
6.2.1 Reimbursement for
Non-Laxative Prescription OIC Therapies in Europe 85
6.2.2 Defined Treatment Guidelines
for OIC 87
6.2.3 Improved Physician Awareness
and Diagnosis of OIC 88
6.2.4 Improved Patient and
Physician Awareness of Prescription Drugs Available for the Treatment
of OIC 90
6.2.5 Clinical Data Assessing
Laxative Efficacy 91
6.3 Opportunity Analysis 93
6.3.1 Launch of an Extensive
Marketing Campaign 93
6.3.2 Treatments that Target Other
OBD Symptoms 94
6.3.3 Label Expansion of Approved
Constipation Drugs into OIC 95
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
Comments
Post a Comment